Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000388025> ?p ?o ?g. }
- W2000388025 endingPage "274" @default.
- W2000388025 startingPage "269" @default.
- W2000388025 abstract "Background and Purpose No treatments have been identified to lower the risk of intracerebral hemorrhage due to cerebral amyloid angiopathy (CAA). A potential approach to prevention is the use of agents that interfere with the pathogenic cascade initiated by the β-amyloid peptide (Aβ). Tramiprosate (3-amino-1-propanesulfonic acid) is a candidate molecule shown in preclinical studies to reduce CAA in a transgenic mouse model. Methods We performed a 5-center phase 2 double-blinded trial to evaluate the safety, tolerability, and pharmacokinetics of tramiprosate in subjects with lobar intracerebral hemorrhage. Twenty-four subjects age ≥55 years with possible or probable CAA were randomized to receive 12 weeks of tramiprosate at 1 of 3 oral doses (50, 100, or 150 mg twice daily). Subjects were followed for clinical adverse effects, laboratory, vital sign, electrocardiogram, cognitive, or functional changes, appearance of new symptomatic or asymptomatic hemorrhages, and pharmacokinetic parameters. Results Enrolled subjects were younger (mean age 70.8±5.4, range 61 to 78) and had more advanced baseline disease (measured by number of previous hemorrhages) than consecutive subjects in a CAA natural history cohort. No concerning safety issues were encountered with treatment. Nausea and vomiting were the most common adverse events and were more frequent at high doses. Nine subjects had new symptomatic or asymptomatic hemorrhages during treatment; all occurred in subjects with advanced baseline disease, with no apparent effect of drug dosing assignment. Conclusions These data suggest that tramiprosate can be given safely to subjects with suspected CAA and support future efficacy trials." @default.
- W2000388025 created "2016-06-24" @default.
- W2000388025 creator A5006664647 @default.
- W2000388025 creator A5006769565 @default.
- W2000388025 creator A5015783013 @default.
- W2000388025 creator A5026850937 @default.
- W2000388025 creator A5032361495 @default.
- W2000388025 creator A5035635520 @default.
- W2000388025 creator A5042416344 @default.
- W2000388025 creator A5045904720 @default.
- W2000388025 creator A5062339766 @default.
- W2000388025 creator A5063509357 @default.
- W2000388025 creator A5068147172 @default.
- W2000388025 creator A5090917504 @default.
- W2000388025 date "2006-10-01" @default.
- W2000388025 modified "2023-10-04" @default.
- W2000388025 title "A Phase 2 Study of Tramiprosate for Cerebral Amyloid Angiopathy" @default.
- W2000388025 cites W1674692411 @default.
- W2000388025 cites W1833346013 @default.
- W2000388025 cites W1953027527 @default.
- W2000388025 cites W1974604086 @default.
- W2000388025 cites W1977238326 @default.
- W2000388025 cites W1982341565 @default.
- W2000388025 cites W1995335567 @default.
- W2000388025 cites W1996849399 @default.
- W2000388025 cites W1998801224 @default.
- W2000388025 cites W2014667778 @default.
- W2000388025 cites W2016698723 @default.
- W2000388025 cites W2018773958 @default.
- W2000388025 cites W2025313184 @default.
- W2000388025 cites W2027123157 @default.
- W2000388025 cites W2068808615 @default.
- W2000388025 cites W2076779801 @default.
- W2000388025 cites W2103997070 @default.
- W2000388025 cites W2135148614 @default.
- W2000388025 cites W2165293684 @default.
- W2000388025 cites W2338858604 @default.
- W2000388025 doi "https://doi.org/10.1097/01.wad.0000213845.28624.f4" @default.
- W2000388025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17132972" @default.
- W2000388025 hasPublicationYear "2006" @default.
- W2000388025 type Work @default.
- W2000388025 sameAs 2000388025 @default.
- W2000388025 citedByCount "38" @default.
- W2000388025 countsByYear W20003880252012 @default.
- W2000388025 countsByYear W20003880252013 @default.
- W2000388025 countsByYear W20003880252014 @default.
- W2000388025 countsByYear W20003880252015 @default.
- W2000388025 countsByYear W20003880252016 @default.
- W2000388025 countsByYear W20003880252017 @default.
- W2000388025 countsByYear W20003880252018 @default.
- W2000388025 countsByYear W20003880252019 @default.
- W2000388025 countsByYear W20003880252020 @default.
- W2000388025 countsByYear W20003880252021 @default.
- W2000388025 countsByYear W20003880252022 @default.
- W2000388025 countsByYear W20003880252023 @default.
- W2000388025 crossrefType "journal-article" @default.
- W2000388025 hasAuthorship W2000388025A5006664647 @default.
- W2000388025 hasAuthorship W2000388025A5006769565 @default.
- W2000388025 hasAuthorship W2000388025A5015783013 @default.
- W2000388025 hasAuthorship W2000388025A5026850937 @default.
- W2000388025 hasAuthorship W2000388025A5032361495 @default.
- W2000388025 hasAuthorship W2000388025A5035635520 @default.
- W2000388025 hasAuthorship W2000388025A5042416344 @default.
- W2000388025 hasAuthorship W2000388025A5045904720 @default.
- W2000388025 hasAuthorship W2000388025A5062339766 @default.
- W2000388025 hasAuthorship W2000388025A5063509357 @default.
- W2000388025 hasAuthorship W2000388025A5068147172 @default.
- W2000388025 hasAuthorship W2000388025A5090917504 @default.
- W2000388025 hasConcept C126322002 @default.
- W2000388025 hasConcept C127413603 @default.
- W2000388025 hasConcept C141071460 @default.
- W2000388025 hasConcept C197934379 @default.
- W2000388025 hasConcept C2777094939 @default.
- W2000388025 hasConcept C2777736543 @default.
- W2000388025 hasConcept C2777790613 @default.
- W2000388025 hasConcept C2777910003 @default.
- W2000388025 hasConcept C2778375690 @default.
- W2000388025 hasConcept C2779134260 @default.
- W2000388025 hasConcept C2779483572 @default.
- W2000388025 hasConcept C2780580376 @default.
- W2000388025 hasConcept C2780645631 @default.
- W2000388025 hasConcept C535046627 @default.
- W2000388025 hasConcept C71924100 @default.
- W2000388025 hasConcept C72563966 @default.
- W2000388025 hasConcept C78519656 @default.
- W2000388025 hasConcept C90924648 @default.
- W2000388025 hasConceptScore W2000388025C126322002 @default.
- W2000388025 hasConceptScore W2000388025C127413603 @default.
- W2000388025 hasConceptScore W2000388025C141071460 @default.
- W2000388025 hasConceptScore W2000388025C197934379 @default.
- W2000388025 hasConceptScore W2000388025C2777094939 @default.
- W2000388025 hasConceptScore W2000388025C2777736543 @default.
- W2000388025 hasConceptScore W2000388025C2777790613 @default.
- W2000388025 hasConceptScore W2000388025C2777910003 @default.
- W2000388025 hasConceptScore W2000388025C2778375690 @default.
- W2000388025 hasConceptScore W2000388025C2779134260 @default.
- W2000388025 hasConceptScore W2000388025C2779483572 @default.
- W2000388025 hasConceptScore W2000388025C2780580376 @default.